Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors

0:00-12:02

Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the...

Publisher

CME in Minutes: Education in Gastroenterology

Link

answersincme.com/DDP860

Published

July 1, 2025

Duration

12 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

Answers in CME

CI

CME in Minutes: Education in Gastroenterology

@cmeinminuteseducationingastr

#tumorperspective #pretreatedpatients #advancedsolidtumors #lifesciences #medicine

The Nile